TRXB
TRex Bio, Inc.
Price Chart
Latest Quote
$13.79
-0.08 (-0.58%)
Current Price
| Previous Close | $13.87 |
| Open | $14.00 |
| Day High | $14.14 |
| Day Low | $13.69 |
| Volume | 42,864 |
Stock Information
| Shares Outstanding | 27.45M |
| Total Debt | $197K |
| Cash Equivalents | $90.85M |
| Net Income | $-46.39M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $378.48M |
| EPS (TTM) | $-2.47 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $183.99M |
| Income | $-46.39M |
| Book/sh | $-25.40 |
| Cash/sh | $3.31 |
| Employees | 60 |
Financial Ratios
| Quick Ratio | 11.87 |
| Current Ratio | 12.18 |
| Debt/Eq | 0.23 |
Returns & Margins
Ownership
| Insider Ownership | 41.65% |
| Institutional Ownership | 31.70% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -0.54 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 2.38M |
Performance History
| Week | -4.50% |
| YTD | -1.50% |
| 10 Years | -1.50% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $13.79 | 42,900 |
| 2026-10-26 | $13.87 | 55,000 |
| 2026-10-23 | $13.81 | 81,200 |
| 2026-10-22 | $15.50 | 67,500 |
| 2026-10-21 | $15.24 | 88,600 |
| 2026-10-20 | $14.44 | 64,200 |
| 2026-10-19 | $14.80 | 113,500 |
| 2026-10-16 | $14.01 | 81,900 |
| 2026-10-15 | $14.16 | 88,700 |
| 2026-10-14 | $13.50 | 398,800 |
| 2026-10-13 | $13.60 | 121,900 |
| 2026-10-12 | $14.03 | 189,000 |
| 2026-10-09 | $14.00 | 1,257,000 |
About TRex Bio, Inc.
TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally. The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and treg function to identify and characterize therapeutic targets, using computational mapping, which uses in silico tools and a human tissue bank and atlas of human treg gene expression to identify pathways in tissue immune regulation; the Treg Atlas, which recreates tissue states in tregs and reprograms blood-derived Tregs to recreate human tissue-specific pathways in vitro for target validation; and the Phenotypic Assay Cascade, a suite of high-throughput functional fingerprinting assays that test targets across donors and inflammatory contexts. The company develops TRB-061 an investigational tumor necrosis factor receptor 2 (TNFR2) agonist and fragment crystallizable-fusion (Fc-fusion) protein designed to selectively agonize TNFR2 to activate and expand Tregs in inflamed tissues. The company also develops TRB-071, an agonist designed to augment tissue Tregs and block an inflammatory signaling pathway, for inflammatory bowel disease. Additionally, it advances TRB-051, a partnered modulator of immune effector cells, for autoimmune and inflammatory diseases including lupus with cutaneous involvement. The company also advances preclinical-stage programs addressing tissue Treg biology informed by the Deep Biology Platform. TRex Bio, Inc. was incorporated in 2018 and is based in South San Francisco, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on TRXB.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $39,108,000 |
| Operating Revenue | $0 | $39,108,000 |
| Expenses | ||
| Total Expenses | $37,845,000 | $41,489,000 |
| Other Income Expense | $-69,000 | $-70,000 |
| Other Non Operating Income Expenses | $-69,000 | $-70,000 |
| Net Non Operating Interest Income Expense | $3,154,000 | $2,007,000 |
| Operating Expense | $37,845,000 | $41,489,000 |
| General And Administrative Expense | $8,036,000 | $6,500,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-34,806,000 | $-3,144,000 |
| Net Interest Income | $3,154,000 | $2,007,000 |
| Interest Income | $3,154,000 | $2,007,000 |
| Normalized Income | $-34,806,000 | $-3,144,000 |
| Net Income From Continuing And Discontinued Operation | $-34,806,000 | $-3,144,000 |
| Total Operating Income As Reported | $-37,845,000 | $-2,381,000 |
| Net Income Common Stockholders | $-34,806,000 | $-8,889,000 |
| Net Income | $-34,806,000 | $-3,144,000 |
| Net Income Including Noncontrolling Interests | $-34,806,000 | $-3,144,000 |
| Net Income Continuous Operations | $-34,806,000 | $-3,144,000 |
| Pretax Income | $-34,760,000 | $-444,000 |
| Interest Income Non Operating | $3,154,000 | $2,007,000 |
| Operating Income | $-37,845,000 | $-2,381,000 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-37,627,000 | $-1,122,000 |
| Reconciled Depreciation | $218,000 | $1,259,000 |
| EBITDA (Bullshit earnings) | $-37,627,000 | $-1,122,000 |
| EBIT | $-37,845,000 | $-2,381,000 |
| Diluted NI Availto Com Stockholders | $-34,806,000 | $-8,889,000 |
| Tax Provision | $46,000 | $2,700,000 |
| Research And Development | $29,809,000 | $34,989,000 |
| Selling General And Administration | $8,036,000 | $6,500,000 |
| Other Gand A | $8,036,000 | $6,500,000 |
| Preferred Stock Dividends | - | $5,745,000 |
Fetched: 2026-10-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-92,119,000 | $-57,972,000 |
| Total Assets | $73,133,000 | $68,066,000 |
| Total Non Current Assets | $1,701,000 | $1,292,000 |
| Other Non Current Assets | $538,000 | $3,000 |
| Current Assets | $71,432,000 | $66,774,000 |
| Prepaid Assets | $3,707,000 | $1,469,000 |
| Cash Cash Equivalents And Short Term Investments | $67,725,000 | $65,305,000 |
| Cash And Cash Equivalents | $15,192,000 | $47,469,000 |
| Debt | ||
| Total Debt | $717,000 | $696,000 |
| Current Debt And Capital Lease Obligation | $717,000 | $696,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $165,252,000 | $126,038,000 |
| Total Non Current Liabilities Net Minority Interest | $160,258,000 | $118,499,000 |
| Other Non Current Liabilities | $72,000 | - |
| Tradeand Other Payables Non Current | $1,171,000 | $1,253,000 |
| Current Liabilities | $4,994,000 | $7,539,000 |
| Other Current Liabilities | $280,000 | $153,000 |
| Payables And Accrued Expenses | $3,997,000 | $6,690,000 |
| Payables | $519,000 | $2,514,000 |
| Total Tax Payable | $148,000 | $1,987,000 |
| Income Tax Payable | $148,000 | $1,987,000 |
| Accounts Payable | $371,000 | $527,000 |
| Equity | ||
| Common Stock Equity | $-92,119,000 | $-57,972,000 |
| Total Equity Gross Minority Interest | $-92,119,000 | $-57,972,000 |
| Stockholders Equity | $-92,119,000 | $-57,972,000 |
| Gains Losses Not Affecting Retained Earnings | $17,000 | $8,000 |
| Other Equity Adjustments | $17,000 | $8,000 |
| Retained Earnings | $-94,259,000 | $-59,453,000 |
| Preferred Securities Outside Stock Equity | $159,015,000 | $117,246,000 |
| Other | ||
| Tangible Book Value | $-92,119,000 | $-57,972,000 |
| Invested Capital | $-92,119,000 | $-57,972,000 |
| Working Capital | $66,438,000 | $59,235,000 |
| Capital Lease Obligations | $717,000 | $696,000 |
| Total Capitalization | $-92,119,000 | $-57,972,000 |
| Additional Paid In Capital | $2,122,000 | $1,472,000 |
| Capital Stock | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 |
| Current Capital Lease Obligation | $717,000 | $696,000 |
| Current Accrued Expenses | $3,478,000 | $4,176,000 |
| Net PPE | $1,163,000 | $1,289,000 |
| Accumulated Depreciation | $-4,430,000 | $-4,212,000 |
| Gross PPE | $5,593,000 | $5,501,000 |
| Other Properties | $5,584,000 | $5,492,000 |
| Machinery Furniture Equipment | $9,000 | $9,000 |
| Other Short Term Investments | $52,533,000 | $17,836,000 |
Fetched: 2026-10-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-41,426,000 | $-25,650,000 |
| Operating Activities | ||
| Operating Cash Flow | $-41,358,000 | $-25,582,000 |
| Cash Flow From Continuing Operating Activities | $-41,358,000 | $-25,582,000 |
| Investing Activities | ||
| Capital Expenditure | $-68,000 | $-68,000 |
| Investing Cash Flow | $-32,989,000 | $-17,304,000 |
| Cash Flow From Continuing Investing Activities | $-32,989,000 | $-17,304,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $42,080,000 | $42,325,000 |
| Financing Cash Flow | $42,070,000 | $41,851,000 |
| Cash Flow From Continuing Financing Activities | $42,070,000 | $41,851,000 |
| Net Other Financing Charges | $-10,000 | $-474,000 |
| Net Preferred Stock Issuance | $41,779,000 | $42,279,000 |
| Preferred Stock Issuance | $41,779,000 | $42,279,000 |
| Net Common Stock Issuance | $301,000 | $46,000 |
| Common Stock Issuance | $301,000 | $46,000 |
| Other | ||
| Income Tax Paid Supplemental Data | $0 | $2,487,000 |
| End Cash Position | $15,192,000 | $47,469,000 |
| Beginning Cash Position | $47,469,000 | $48,504,000 |
| Changes In Cash | $-32,277,000 | $-1,035,000 |
| Net Investment Purchase And Sale | $-32,921,000 | $-17,236,000 |
| Sale Of Investment | $98,000,000 | $24,000,000 |
| Purchase Of Investment | $-130,921,000 | $-41,236,000 |
| Net PPE Purchase And Sale | $-68,000 | $-68,000 |
| Purchase Of PPE | $-68,000 | $-68,000 |
| Change In Working Capital | $-6,777,000 | $-24,620,000 |
| Change In Other Current Liabilities | $-1,325,000 | $-1,268,000 |
| Change In Other Current Assets | $-535,000 | $0 |
| Change In Payables And Accrued Expense | $-2,679,000 | $179,000 |
| Change In Accrued Expense | $-2,441,000 | $490,000 |
| Change In Payable | $-238,000 | $-311,000 |
| Change In Account Payable | $-156,000 | $-588,000 |
| Change In Tax Payable | $-82,000 | $277,000 |
| Change In Income Tax Payable | $-82,000 | $277,000 |
| Change In Prepaid Assets | $-2,238,000 | $577,000 |
| Other Non Cash Items | $1,322,000 | $1,267,000 |
| Stock Based Compensation | $452,000 | $248,000 |
| Amortization Of Securities | $-1,767,000 | $-592,000 |
| Depreciation Amortization Depletion | $218,000 | $1,259,000 |
| Depreciation And Amortization | $218,000 | $1,259,000 |
| Net Income From Continuing Operations | $-34,806,000 | $-3,144,000 |
| Change In Other Working Capital | - | $-24,108,000 |
Fetched: 2026-10-24